Summary
Development of turbinmicin analogs as a new class of safe and effective antifungal drugs against pan-drug resistant fungal pathogens, focusing on lead optimization, efficacy, safety, and production/formulation.
Symbiotic-based discovery of turbinmicin, a safe and selective antifungal against resistant fungi
US · IL
NIH
grant
awarded
#nih-5R01AI167883-04
What they want
The project aims to develop turbinmicin, a novel natural product antifungal, through lead optimization. The work is divided into three aims: efficacy (specific aim 1), safety (specific aim 2), and production/formulation (specific aim 3). Each aim has two sequential stages. Stage 1 will identify the most promising lead analog based on efficacy, safety, and solubility screens. Stage 2 will delineate IND-enabling PK/PD efficacy and safety in established murine and rat models. The overall goal is to provide IND-enabling datasets for clinical development of a new class of antifungal.
Deliverables
- IND-enabling datasets for clinical development of a new class of antifungal
Technical requirements
- IND-enabling PK/PD efficacy and safety in established murine models
- IND-enabling PK/PD efficacy and safety in established rat models
Risks & flags
Incumbent: Wisconsin Drug Discovery and Development Center
